Nitrogen Containing Patents (Class 514/727)
  • Patent number: 10105350
    Abstract: A method of cross-linking collagen present in a collagenous tissue comprising contacting the collagenous tissue with an amount of a formaldehyde releasing agent effective to crosslink the collagen is provided. A method of inhibiting loss of structural integrity of a collagenous tissue during transplantation-related transport comprising contacting the collagenous tissue with an amount of a formaldehyde releasing agent effective to inhibit loss of structural integrity of the collagenous tissue is also provided. A composition for ophthalmic administration comprising a formaldehyde releasing agent, sodium bicarbonate, and ophthalmically suitable carriers or excipients is also provided. Finally, a method of altering the refractive power of a cornea comprising contacting the cornea with a formaldehyde releasing agent so as to effect cross-linking in the cornea and thereby alter the refractive power of the cornea is provided.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: October 23, 2018
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: David Choohyun Paik, Stephen Lewis Trokel
  • Patent number: 9034929
    Abstract: Biocidal compositions and their use in aqueous media, such as metalworking fluids, the compositions comprising a biocidal agent; and a non-biocidal primary amino alcohol compound of the formula (I); wherein R1, R2, R3, R4, and R5 are as defined herein.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: May 19, 2015
    Assignee: ANGUS Chemical Company
    Inventors: Charles E. Coburn, John L. Pohlman, Bonnie A. Pyzowski, Patrick E. Brutto, George David Green, Raymond J. Swedo
  • Patent number: 8993638
    Abstract: Provided are biocidal compositions comprising: tris(hydroxymethyl)nitromethane; and a brominated nitroalkanol compound of formula I: wherein R1, R2, and R3 are as defined herein. The compositions are useful for controlling microorganisms in aqueous or water-containing systems.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: March 31, 2015
    Assignee: Dow Global Technologies LLC
    Inventor: Bei Yin
  • Publication number: 20140369953
    Abstract: Disclosed are compositions comprising a) an antimicrobial agent, which is selected from the group consisting of biocides containing halogen atoms and/or containing phenolic moieties, formic acid, chlorine dioxide, chlorine dioxide generating compounds, dialdehydes; components containing an antimicrobial metal such as antimicrobial silver, and b) a polyamine, especially a polyethylenimine. The polyamine is effective as a booster for the antimicrobial agent.
    Type: Application
    Filed: February 19, 2013
    Publication date: December 18, 2014
    Applicant: BASF SE
    Inventors: Janina Purschwitz, Stephan Hüffer, Alejandra Garcia Marcos, Menno Hazenkamp
  • Publication number: 20140315792
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: February 14, 2014
    Publication date: October 23, 2014
    Inventors: Rolf Wagner, John K. Pratt, Dachun Liu, Michael D. Tufano, David A. DeGoey, Warren M. Kati, Charles W. Hutchins, Pamela L. Dooner, John T. Randolph, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, Mark A. Matulenko, Ryan G. Keddy, Tammie K. Jinkerson, Todd W. Rockway, Clarence J. Maring, Douglas K. Hutchinson, Charles A. Flentge, David A. Betebenner, Kathy Sarris, Kevin R. Woller, Seble H. Wagaw, Jean C. Califano, Wenke Li, Daniel D. Caspi, Mary E. Bellizzi, Yi Gao, Allan C. Krueger
  • Publication number: 20140256805
    Abstract: The present disclosure is generally directed to neuroactive substituted cyclopenta[b]phenanthrenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 11, 2014
    Inventor: Douglas Covey
  • Patent number: 8828414
    Abstract: Provided are biocidal compositions comprising 2,6-dimethyl-m-dioxane-4-ol acetate and a non-formaldehyde releasing biocidal compound selected from the group consisting of: a brominated nitroalkanol, a 2-halo-2-(halomethyl)glutaronitrile, and 2-phenoxyethanol. The compositions are useful for controlling microorganisms in aqueous or water containing systems.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: September 9, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Kathy J. Ji, Donald J. Love, Jon B. Raymond
  • Publication number: 20140221319
    Abstract: The invention provides methods and compositions for inhibiting CD 38 activity, and methods of treating or preventing various disorders associated with CD38 activity.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 7, 2014
    Applicants: Mayo Foundation for Medical Education and Research, President and Fellows of Harvard College
    Inventors: David A. Sinclair, Nathan L. Price, Eduardo N. Chini, Jon C. Clardy, Shugeng Cao
  • Patent number: 8741967
    Abstract: The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. This invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: June 3, 2014
    Assignees: Children's Hospital & Research Center at Oakland, Research Foundation of the City University of New York
    Inventors: Julie D. Saba, Henrik Fyrst, Robert Bittman
  • Patent number: 8673366
    Abstract: The present invention provides pharmaceutical compositions and methods for making the same, which are highly effective against cancer, viruses, amoebae, bacteria (both gram-negative and -positive), fungi, algae, bacterial spores, yeast, and the like. The compounds preferably rely on employing the synergistic effect of organo-metal compounds and the concomitant generation of reactive oxygen species (ROS) through the agency of reducing cofactors. The aqueous solution may be condensed and dried using conventional methods available to those skilled in the art to produce gels as well as solids, such as tablets or powders. Solid forms include tablets, capsules, suppositories, and the like or mixtures thereof. In addition, the solid form of the present compositions may be activated upon solubilization in a liquid.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: March 18, 2014
    Inventor: Kareem I. Batarseh
  • Patent number: 8637088
    Abstract: An antimicrobial composition contains a soluble silver salt and an alkanolamine or aminoalcohol. The composition may additionally contain an amino acid or amino acid salt and surfactant. The composition has additional stability and activity compared to prior art silver complexes.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: January 28, 2014
    Assignee: The Clorox Company
    Inventors: David R. Scheuing, Erika Szekeres, Steven Bromberg
  • Patent number: 8535729
    Abstract: An antimicrobial composition contains a soluble silver salt and an alkanolamine or aminoalcohol. The composition may additionally contain an amino acid or amino acid salt and surfactant. The composition has additional stability and activity compared to prior art silver complexes.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: September 17, 2013
    Assignee: The Clorox Company
    Inventors: David R. Scheuing, Erika Szekeres, Steven Bromberg
  • Patent number: 8513310
    Abstract: The invention relates to novel cosmetic uses of phytosphingosine or of one of its cosmetically acceptable salts, particularly its hydrochloride, as a slimming agent and/or as an active agent which stimulates the synthesis of leptin by adipocytes, for preparing a cosmetic composition intended for reducing subcutaneous excess fat. The invention also relates to a method of cosmetic treatment intended for obtaining a slimming effect on the human body according to which a cosmetic composition containing phytosphingosine or one of its cosmetically acceptable salts, particularly its hydrochloride, is applied on the parts of the body to be treated. The invention also relates to novel cosmetic compositions containing phytosphingosine or one of its cosmetically acceptable salts, particularly its hydrochloride, in combination with a lipolytic agent selected from the group consisting of CAMP and its derivatives, adenylate cyclase enzyme activating agents and phosphodiesterase enzyme inhibiting agents.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: August 20, 2013
    Assignee: LVMH Recherche
    Inventors: Jocelyne Franchi, Françoise Pellicier
  • Patent number: 8466203
    Abstract: A method for stabilizing collagenous eye tissues by nitrite and nitroalcohol treatment. The topical stiffening agent contains sodium nitrite or a nitroalcohol in a buffered balanced salt solution and can be applied to the surface of the eye on a daily basis for a prolonged period. Application of the solution results in progressive stabilization of the corneal and scleral tissues through non-enzymatic cross-linking of collagen fibers. The compounds can penetrate into the corneal stroma without the need to remove the corneal epithelium. In addition, ultraviolet light is not needed to activate the cross-linking process. The resulting stabilization of corneal and scleral tissues can prevent future alterations in corneal curvature and has utility in diseases such as keratoconus, keratectasia, progressive myopia, and glaucoma.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: June 18, 2013
    Inventors: David Choohyun Paik, Stephen Lewis Trokel
  • Patent number: 8445521
    Abstract: A synergistic antimicrobial composition. The composition contains at least two components. The first component is ortho-phenylphenol or its alkali metal or ammonium salts. The second component is 4,4-dimethyloxazolidine (DMOZ).
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: May 21, 2013
    Assignee: Dow GLobal Technologies LLC
    Inventor: Bei Yin
  • Patent number: 8426474
    Abstract: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: April 23, 2013
    Assignee: Teva Animal Health, Inc.
    Inventors: Richard Farng, Steven Mrha
  • Patent number: 8388949
    Abstract: The invention relates to the field of food compositions and their use. In particular compositions comprising at least 15 En % protein and pantothenic acid, or equivalents thereof, are provided, which are suitable for stimulating appetite.
    Type: Grant
    Filed: December 24, 2004
    Date of Patent: March 5, 2013
    Assignee: N.V. Nutricia
    Inventor: Robert Johan Joseph Hageman
  • Publication number: 20130045949
    Abstract: Described herein are compounds that may be selectively activated to produce active anti-cancer agents in tumor cells. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of treating cancer using the compounds.
    Type: Application
    Filed: July 1, 2012
    Publication date: February 21, 2013
    Applicant: UWM RESEARCH FOUNDATION, INC.
    Inventors: Xiaohua Peng, Yunyan Kuang, Sheng Cao, Wenbing Chen, Yibin Wang
  • Patent number: 8323674
    Abstract: A biocide composition, comprising 2-methylisothiazolin-3-one as a biocidal active ingredient and at least one further biocidal active ingredient, as an additive to materials capable of being attacked by harmful microorganisms, wherein the composition comprises a pyrithione as the further biocidal active ingredient.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: December 4, 2012
    Assignee: Thor GmbH
    Inventors: Dagmar Antoni-Zimmermann, Rudiger Baum, Hans-Jurgen Schmidt, Thomas Wunder
  • Patent number: 8304453
    Abstract: The invention concerns a composition containing at least an alkanolamide, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an oxazolin, an oxazolidinone and a carbamic acid derivative. The invention also concerns the use of such a composition as medicine, in particular its use for preventing or treating skin pathologies of allergic and/or inflammatory and/or irritative origin or resulting from a danger signal. The invention further concerns a method for cosmetic treatment of sensitive, irritated, intolerant, allergy-prone, ageing skin and/or mucosa exhibiting skin barrier disorder, or exhibiting non-pathological immunologic imbalance, which consists in applying such a composition on the skin and/or mucosa.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: November 6, 2012
    Assignee: Laboratoires Expanscience
    Inventors: Philippe Msika, Nathalie Piccardi, Antoine Piccirilli
  • Publication number: 20120276152
    Abstract: Methods and systems for treating an infarct by delivery of zinc chelator to modulate tissue.
    Type: Application
    Filed: February 6, 2012
    Publication date: November 1, 2012
    Inventors: Syed Hossainy, John Stankus, Mikael Trollsas, Dariush Davalian
  • Patent number: 8282952
    Abstract: The invention relates to insect attractants containing compounds with pentagonal heterocyclic structures that are effective in attracting fruitflies.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: October 9, 2012
    Assignee: Activetrad (Proprietary) Limited
    Inventor: Christoffel J. Smit
  • Patent number: 8232300
    Abstract: A compound represented by the following general formula (I): [wherein R1 represents hydrogen atom or a C1-6 alkyl group, A and B represent —(CH2)2—, —(CH2)3—or —(CH2)4—, X represents —N(R2)—CO—(R2 represents hydrogen atom or a C1-6 alkyl group), —CO—N(R3)—(R3 represents hydrogen atom or a C1-6 alkyl group), —C(R4)?C(R5)—(R4 and R5 represent hydrogen atom or a C1-6 alkyl group), or —N(R6)—SO2—(R6 represents hydrogen atom or a C1-6 alkyl group), and Ar represents an aryldiyl group or a heteroaryldiyl group], which has a retinoid action and is useful as an active ingredient of a medicament.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: July 31, 2012
    Assignee: Research Foundation Itsuu Laboratory
    Inventors: Yohei Amano, Masayuki Noguchi, Koichi Shudo
  • Publication number: 20120184436
    Abstract: A synergistic antimicrobial composition. The composition contains at least two components. The first component is ortho-phenylphenol or its alkali metal or ammonium salts. The second component is 4,4-dimethyloxazolidine (DMOZ).
    Type: Application
    Filed: September 15, 2010
    Publication date: July 19, 2012
    Inventor: Bei Yin
  • Patent number: 8178584
    Abstract: The present invention relates to a water-in-oil emulsified composition containing a sphingosine represented by the following formula (1): (R1 represents a hydrocarbon group optionally having a substituent; Y represents methylene, methine or O; X1, X2 and X3 each represent H, OH or acetoxy group; X4 represents H, acetyl group or the like; R2, R3 each represents H, OH or the like; R represents H, amidino group or the like; and a stands for 2 or 3), (B) a C6-30 fatty acid, and (C) an oil component. This water-in-oil emulsified composition has excellent stability and provides a good feeling to skin upon use.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: May 15, 2012
    Assignee: Kao Corporation
    Inventors: Koji Okubo, Yumiko Yamamoto
  • Patent number: 8168232
    Abstract: The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: May 1, 2012
    Assignee: Queen's University at Kingston
    Inventors: Charles H. Graham, Lynne-Marie Postovit, Michael A. Adams, Jeremy P. W. Heaton
  • Patent number: 8092840
    Abstract: A nutritional supplement for enhancing sleep and lucid dreaming in humans. It contains a combination of ingredients in proportions calculated to enhance lucid dreaming. The primary ingredients are Calea ternifolia, L-5-Hydroxytryptophan (L-5-HTP), and Vinpocetine. In addition, the nutritional supplement may include the secondary ingredient Melatonin and the tertiary ingredients Wild Lettuce Extract, Mugwort Extract, Dimethylaminoethanol Powder (DMAE), Passionflower Extract and Green Tea Extract. Further, various Vitamins may be added such as certain B vitamins, D and C, as well as Zinc, Magnesium and Calcium. The selection and amounts of the ingredients of the nutritional supplement promotes sleep and lucid dreaming in people who have taken the nutritional supplement prior to going to sleep.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: January 10, 2012
    Inventor: Jeff Luciano
  • Patent number: 8048996
    Abstract: The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as a plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, can be effectively used in delivering various biologically active molecules.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: November 1, 2011
    Assignees: Postech Foundation, Postech Academy-Industry Foundation
    Inventors: Sung-Kee Chung, Kaustabh Kumar Maiti, Woo Sirl Lee, Ock-Youm Jeon, Seok-Ho Lee
  • Patent number: 8003704
    Abstract: Use is disclosed of (a) an AlDH-inhibitory amount of a Trp metabolite, or an analogue or derivative thereof or (b) a bioprecursor thereof, or (c) a potentiator of (a) and/or (b), in the preparation of a medicament for treating alcoholism and/or alcohol dependence.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: August 23, 2011
    Inventor: Abdulla Abu-Bakr Badawy
  • Patent number: 7999010
    Abstract: Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5 and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: August 16, 2011
    Assignee: Aquinox Pharmaceuticals Inc.
    Inventors: Jeffery R. Raymond, Kang Han, Yuanlin Zhou, Yuehua He, Bradley Noren, James Gee Ken Yee
  • Patent number: 7981439
    Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: July 19, 2011
    Assignee: Acura Pharmaceuticals, Inc.
    Inventors: Vijai Kumar, David Dixon, Divya Tewari, Dilip B. Wadgaonkar
  • Patent number: 7973084
    Abstract: The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, it can be effectively used in delivering various biologically active molecules, such as doxorubicin and paclitaxel to target cells.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: July 5, 2011
    Assignee: Postech Academy-Industrial Foundation
    Inventors: Sung-Kee Chung, Woo Sirl Lee, Kaustabh Kumar Maiti
  • Publication number: 20110159304
    Abstract: Disclosed are a composition for inhibiting a proliferation of sulphate reducing bacteria comprising at least one of 1,2-benzisothiazol-3(2H)-one, irgasan, benzyl-2-bromoacetate, 2,2-dibromo-2-cyanoacetamide, and 2-bromo-2-nitropropan-1,3-diol as effective ingredients; a method for inhibiting the proliferation of sulphate reducing bacteria comprising the step of including a sufficient amount for inhibiting the proliferation of sulphate reducing bacteria of at least one of 1,2-benzisothiazol-3(2H)-one, irgasan, benzyl-2-bromoacetate, 2,2-dibromo-2-cyanoacetamide, and 2-bromo-2-nitropropan-1,3-diol in a corrosion sensitive material or degradation sensitive material; a sheet comprising the composition; and a steel plate to which the composition is applied.
    Type: Application
    Filed: June 2, 2010
    Publication date: June 30, 2011
    Applicant: KOREA GAS CORPORATION
    Inventors: Hong Seok Song, Young Geun Kim, Keun Chang Ryu, Young Min Baek, Young Hyo Chang
  • Publication number: 20110152365
    Abstract: In the present invention, there is provided a disinfectant composition comprising (a) 15% to 49.75% biocide, by weight based on the weight of said composition, (b) 15% to 49.75% water, by weight based on the weight of said composition, and (c) 0.5% to 60% soluble salt, by weight based on the weight of said composition.
    Type: Application
    Filed: December 14, 2010
    Publication date: June 23, 2011
    Inventors: Antonio Arzu, Ute H. Bertheas, Paul Foley, Stephanie L. Hughes, Philip A. Keene, Pierre M. Lenoir
  • Patent number: 7928147
    Abstract: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: April 19, 2011
    Assignee: Teva Animal Health, Inc.
    Inventors: Richard Farng, Steven Mrha
  • Patent number: 7902261
    Abstract: The present invention aims at providing a pharmaceutical composition for the prophylaxis or treatment, irrespective of the kind of virus, of viral myocarditis or viral diseases induced by viral myocarditis, by the treatment or prevention of the onset of cytotoxicity in various organs, and a method of the prophylaxis or treatment. The present invention also relates to a pharmaceutical composition for the prophylaxis or treatment of viral myocarditis or viral diseases induced by viral myocarditis, which contains 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable salt thereof as an active ingredient. The present invention further relates to a method for the prophylaxis or treatment of viral myocarditis or viral diseases induced by viral myocarditis, which includes administering an effective amount of the aforementioned compound or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: March 8, 2011
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventor: Akira Matsumori
  • Publication number: 20100317744
    Abstract: Provided are biocidal compositions comprising: tris (hydroxymethyl) nitromethane; and a brominated nitroalkanol compound of formula I: wherein R1, R2, and R3 are as defined herein. The compositions are useful for controlling microorganisms in aqueous or water-containing systems.
    Type: Application
    Filed: June 9, 2010
    Publication date: December 16, 2010
    Inventor: Bei Yin
  • Patent number: 7846975
    Abstract: The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as a plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, can be effectively used in delivering various biologically active molecules.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: December 7, 2010
    Assignees: Postech Foundation, Postech Academy-Industry Foundation
    Inventors: Sung-Kee Chung, Kaustabh Kumar Maiti, Woo Sirl Lee, Ock-Youm Jeon, Seok-Ho Lee
  • Publication number: 20100255048
    Abstract: A web material encompasses a bonded fibrous material web of cellulose material that is made of a layer of cellulose fibers that are press-bonded in sections of the fibrous material web. One or several antimicrobial substances are contained in the fibrous material web. The antimicrobial substances are selected from finely dispersed silver and silver salts, antimicrobial metal oxides, solid inorganic acids, solid organic acids, and biocides.
    Type: Application
    Filed: April 2, 2010
    Publication date: October 7, 2010
    Applicant: MCAIRLAID'S VLIESSTOFFE GmbH & CO. KG
    Inventor: Andreas Schmidt
  • Publication number: 20100239678
    Abstract: The present invention is directed to attaching drugs 11 and other functional groups to surfaces of nano-sized diamond particles (NDs) 20 to enhance their efficacy. The method involves hydrating a plurality of nanodiamond (ND) particles 20 having a plurality of carbon chain surface molecules 23 on its surface. Cations 40 are embedded within the lattice structure 21 of the surface molecules 23 of the ND particles 20. The embedded cations 40 attract anions that cause crystalline growth. The anion form of drug molecules 11 are then grown on the crystal to cause the NDs 20 to be coated such that the active sites of said drug molecules 11 point away from the ND particle 20 exposing them for enhanced activity and enhanced drug efficacy. The efficacy of antimicrobial drugs 11, as well as other drugs 11 are enhanced by their attachment to the NDs 20.
    Type: Application
    Filed: June 7, 2010
    Publication date: September 23, 2010
    Inventor: Ali RAZAVI
  • Publication number: 20100234329
    Abstract: The present invention relates to a novel ingestible film composition. More specifically, the invention is directed to a water-based, enzymatically-digested carboxymethylcellulose (CMC-Enz) film composition that is suitable for delivering pharmaceutical drugs, vitamins, natural products and other products to humans and animals. The invention further includes a method for manufacturing the novel composition. Advantageously, the film composition can accommodate an active ingredient in a quantity of up to approximately 60% of the overall weight of the final film.
    Type: Application
    Filed: October 31, 2008
    Publication date: September 16, 2010
    Inventors: Eve Bélanger, Nicole Fortier, Geneviève Nadeau
  • Publication number: 20100222333
    Abstract: Topically applicable pharmaceutical compositions contain at least one pharmaceutically active agent and an effective antimicrobial amount of a preservative excipient mixture and devoid of such amount of known preservative(s) as would otherwise itself impart an effective antimicrobial action thereto.
    Type: Application
    Filed: March 10, 2010
    Publication date: September 2, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Lydie MAITRE
  • Patent number: 7772156
    Abstract: Microbicidal compositions including (a) cyanodithiocarbimate and (b) an N-alkyl heterocyclic compound; a triazole compound or salt thereof or metal complex thereof; a microbicide with an activated halogen atom or a formaldehyde releasing compound; 1,4-bis(bromoacetoxy)-2-butene; 2-(thiocyanomethylthio)benzothiazole; a methylene-bis(thiocyanate); a halogenated acetophenone; a halopropynl compound; an iodosulfone; a phenol; a halocyanoacetamide compound and/or a quaternary ammonium compound are described. Components (a) and (b) can be present in a synergistically effective amount to control the growth of at least one microorganism. Methods for controlling the growth of microorganisms with the compositions are also disclosed.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: August 10, 2010
    Assignee: Buckman Laboratories International, Inc.
    Inventor: Stephen D. Bryant
  • Publication number: 20100173019
    Abstract: A method for stabilizing collagenous eye tissues by nitrite and nitroalcohol treatment. The topical stiffening agent contains sodium nitrite or a nitroalcohol in a buffered balanced salt solution and can be applied to the surface of the eye on a daily basis for a prolonged period. Application of the solution results in progressive stabilization of the corneal and scleral tissues through non-enzymatic cross-linking of collagen fibers. The compounds can penetrate into the corneal stroma without the need to remove the corneal epithelium. In addition, ultraviolet light is not needed to activate the cross-linking process. The resulting stabilization of corneal and scleral tissues can prevent future alterations in corneal curvature and has utility in diseases such as keratoconus, keratectasia, progressive myopia, and glaucoma.
    Type: Application
    Filed: December 6, 2007
    Publication date: July 8, 2010
    Inventors: David Choohyun Paik, Stephen Lewis Trokel
  • Patent number: 7745496
    Abstract: A process for preparing a compound of formula (I) X-(CH2)n-ONO2??(I) wherein: X is a halogen atom selected from Cl, Br, I; n is an integer from 3 to 6; said process comprising the slow addition of a compound of formula (II) X-(CH2)n-OH??(II) wherein X and n are as defined above to a nitrating agent selected from the group consisting of concentrated nitric acid/concentrated sulfuric acid (sulfonitric mixture), nitric acid alone, NaNO2 in trifluoroacetic acid, nitronium salts such as NO2BF4 and an organic solvent selected from the group consisting of CH2Cl2, CHCl3, CCl4, perfluorohexane, perfluoroheptane. The invention refers also to solutions containing: a compound of general formula (I) and a solvent selected from the group consisting of CH2Cl2, CHCl3, CCl4, perfluorohexane, perfluoroheptane, characterized in that the compound of formula (I) is present in a concentration not higher than 20% by weight.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: June 29, 2010
    Assignee: Nicox S.A.
    Inventors: Romano Rivolta, Peter Finlander
  • Patent number: 7737186
    Abstract: The invention relates to novel cosmetic uses of phytosphingosine or of one of its cosmetically acceptable salts, particularly its hydrochloride, as a slimming agent and/or as an active agent which stimulates the synthesis of leptin by adipocytes, for preparing a cosmetic composition intended for reducing subcutaneous excess fat. The invention also relates to a method of cosmetic treatment intended for obtaining a slimming effect on the human body according to which a cosmetic composition containing phytosphingosine or one of its cosmetically acceptable salts, particularly its hydrochloride, is applied on the parts of the body to be treated. The invention also relates to novel cosmetic compositions containing phytosphingosine or one of its cosmetically acceptable salts, particularly its hydrochloride, in combination with a lipolytic agent selected from the group consisting of cAMP and its derivatives, adenylate cyclase enzyme activating agents and phosphodiesterase enzyme inhibiting agents.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: June 15, 2010
    Assignee: LVMH Recherche
    Inventors: Jocelyne Franchi, Françoise Pellicier
  • Patent number: 7718715
    Abstract: A stabilized latex with improved antimicrobial features is disclosed. In preferred embodiments, this latex comprises a mixture of 2-bromo-2-nitro-1,3-propanediol and 4,4-dimethyl-oxazolidine or 2-bromo-2-nitro-1,3-propanediol and 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: May 18, 2010
    Assignee: S.C. Johnson & Son, Inc.
    Inventor: Anita S. Erickson
  • Publication number: 20100087547
    Abstract: A blood-flow decrease preventing agent is used to negate or reduce the decreased oxygen delivery in abdominal organs caused by insufflating gas. Preferably a gas is delivered into the abdominal cavity consisting essentially of the insufflating gas and the blood-flow decrease preventing agent. Very preferably, a gas is used consisting essentially of carbon dioxide as the insufflating gas and ethyl nitrite as the blood-flow to abdominal organ decrease preventing agent.
    Type: Application
    Filed: December 9, 2009
    Publication date: April 8, 2010
    Inventor: Jonathan S. Stamler
  • Publication number: 20100075999
    Abstract: The invention relates to a process for the preparation of anagrelide, and for the preparation of intermediates for use in preparing anagrelide. The invention also relates to the intermediates per se, in particular compounds of Formula (V): where R constitutes a suitable leaving group, which may not be hydrogen. The R group may be selected from: (i) —SiR13, (ii) —CH2Ar, (iii) —COOR2, and (iv) sulfonates such as —SO2R3.
    Type: Application
    Filed: February 6, 2008
    Publication date: March 25, 2010
    Applicant: CIPLA LIMITED
    Inventors: Srinivas Laxminarayan Pathi, Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao
  • Patent number: 7618988
    Abstract: Compounds of formula I in which R has a meaning as indicated in claim 1, or one of their optical isomers or pharmaceutically acceptable salts, used for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders and/or for the treatment of extrapyramidal symptoms (EPS) induced by neuroleptics.
    Type: Grant
    Filed: August 12, 2002
    Date of Patent: November 17, 2009
    Assignee: Merck Patentgesellschaft
    Inventors: Henning Böttcher, Ralf Devant, Maria Devant, legal representative, Gerd Bartoszyk, Hermann Russ, Frank Weber, Christoph Seyfried